SCHEMBL1749677

SCHEMBL1749677

COc1ccccc1Nc1nc(NCC2CCCN2C(=O)OC(C)(C)C)nc(C(=O)O)c1[N+](=O)[O-]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 2/20 0.46
GSK3B P49841 2/20 0.46
NR1I2 O75469 1/20 0.46
AHR P35869 1/20 0.46
CDK5 Q00535 1/20 0.46
CDK5R1 Q15078 1/20 0.46
MAPT P10636 7/20 0.45
TDP1 Q9NUW8 1/20 0.44
KMT2A Q03164 3/20 0.42
POLB P06746 1/20 0.42
RAD52 P43351 1/20 0.42
BLM P54132 1/20 0.42
ATM Q13315 1/20 0.42
GAA P10253 1/20 0.42
TRPV1 Q8NER1 1/20 0.40
PRMT5 O14744 1/20 0.40
OPRD1 P41143 1/20 0.37
MEN1 O00255 2/20 0.37
GPR119 Q8TDV5 1/20 0.37
KDM1A O60341 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749679 1.00 GSK3A (0.46) GSK3AGSK3BNR1I2AHRCDK5
SCHEMBL4232401 0.89 TRPV1 (0.42) GSK3AGSK3BNR1I2AHRCDK5
SCHEMBL1749675 0.83 MAPT (0.39) GSK3AGSK3BNR1I2AHRCDK5
SCHEMBL4235387 0.78 TRPV1 (0.39) KMT2ATRPV1PRMT5OPRD1MEN1
SCHEMBL15575473 0.76 KMT2A (0.50) KMT2APOLBTRPV1PRMT5OPRD1
SCHEMBL4048322 0.76 KDM4E (0.43) GAATRPV1PRMT5OPRD1KDM1A
SCHEMBL28015937 0.76 GSK3A (0.41) GSK3AGSK3BNR1I2AHRCDK5
SCHEMBL28015927 0.76 GSK3A (0.41) GSK3AGSK3BNR1I2AHRCDK5
SCHEMBL4220674 0.74 IGF1R (0.45) GSK3AGSK3BNR1I2AHRCDK5
SCHEMBL18285457 0.72 OPRD1 (0.42) KMT2ATRPV1PRMT5OPRD1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383634-B2 Methods of treatment using heteroaryl compounds and compositions thereof SIGNAL PHARMACEUTICALS, LLC (US) 2013-02-26 US disclosed
US-20110224217-A1 METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF SIGNAL PHARMACEUTICALS, LLC 2011-09-15 US disclosed
US-7968556-B2 Heteroaryl compounds, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC (US) 2011-06-28 US disclosed
EP-2078018-A1 HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2009-07-15 EP disclosed
US-20090042890-A1 Heteroaryl compounds, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2009-02-12 US disclosed
WO-2008051494-A1 HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224217-A1 METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF JAK2, CHEK2, PHKG1 GSK3A 348/4885GSK3B 336/4885NR1I2 1069/4885
US-20090042890-A1 Heteroaryl compounds, compositions thereof, and methods of treatment therewith JAK2, CHEK2, SRC GSK3A 391/4885GSK3B 364/4885NR1I2 958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.